Skip to main content

Ascendis Pharma A/S 6-K, filed Oct 26, 2026

Ascendis Pharma A/S (ASND)

6-K 2026-10-26 For: 2026-10-26
View Original
Added on October 26, 2026

About this 6-K

Ascendis Pharma A/S filed this 6-K on October 26, 2026.

Ascendis Pharma A/S reported TransCon PTH improved kidney function in adults with hypoparathyroidism for up to 5 years: mean eGFR rose 9.6 mL/min/1.73 m^2 by Week 52, and 68.9% achieved ≥ 5 mL/min/1.73 m^2 improvement. AI summary